Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer
Public ClinicalTrials.gov record NCT01724866. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2, Open-Label, Dose-Ranging Study of SPI-2012 (HM10460A) or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Study identification
- NCT ID
- NCT01724866
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Enrollment
- 148 participants
Conditions and interventions
Conditions
Interventions
- Cyclophosphamide Drug
- Docetaxel Drug
- Pegfilgrastim Drug
- SPI-2012 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 24, 2013
- Primary completion
- Aug 11, 2014
- Completion
- Aug 11, 2014
- Last update posted
- Apr 14, 2022
2013 – 2014
United States locations
- U.S. sites
- 10
- U.S. states
- 5
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Center for Cancer Care | Glendale | Arizona | 85306 | — |
| Desert Springs Cancer Care | Scottsdale | Arizona | 85255 | — |
| California Cancer Associates for Research and Excellence | Fresno | California | 93720 | — |
| Beaver Medical Group | Highland | California | 92346 | — |
| California Cancer Associates for Research and Excellence | Los Angeles | California | 92025 | — |
| Innovative Clinical Research Institute | Whittier | California | 90603 | — |
| Kentucky Cancer Clinic | Hazard | Kentucky | 41701 | — |
| New York Oncology Hematology, PC | Albany | New York | 12206 | — |
| North Shore Hematology/Oncology Associates | Setauket | New York | 11733 | — |
| Good Samaritan Hospital, Corvallis | Corvallis | Oregon | 97330 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01724866, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 14, 2022 · Synced May 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01724866 live on ClinicalTrials.gov.